newsfilter
← Latest News
GlobeNewswire·

ALK to present positive phase II data on its tablet for the treatment of peanut allergy at ACAAI 2026

  • ALK will present phase II data from the ALLIANCE trial of its investigational once-daily sublingual immunotherapy (SLIT) tablet for peanut allergy at the ACAAI Annual Scientific Meeting in Phoenix, Arizona from 12 to 16 November 2026.
  • The trial included 150 patients aged 4–65 years who were evaluated on two doses of the tablet compared with placebo.
  • Key findings demonstrate proof-of-concept after six months of maintenance treatment with efficacy observed across all age groups.
  • Treatment-related discontinuations were low, with no reports of treatment-related anaphylaxis or serious adverse events.
  • A clear dose response was observed in the amount of peanut protein patients could tolerate after only six months of treatment.
  • Presentations will be delivered by Dr. Edwin Kim, Prof. Aikaterini Anagnostou, Dr. Anna Nowak-Wegrzyn, Dr. Jacob Glenting, and others during a Product Theater session on Friday, 13 November.
  • Three specific abstracts (IDs: 8070, 8096, 8095) detailing efficacy, tolerability, and immunologic responses will be presented on Friday, 13 November.
  • Dr. Kim and Dr. Glenting stated these results provide momentum to advance the investigational peanut tablet into phase III trials.
  • The ALLIANCE trial, initiated in 2022, was a phase I-II multi-site study in North America designed to assess safety, tolerability, and efficacy of an up-dosing regimen.
  • Peanut allergy affects over 10 million people in Europe, the USA, and Canada, with more than 3 million being children and adolescents.
  • ALK is a global specialty pharmaceutical company headquartered in Denmark focused on allergy diagnostics and treatments.
  • The press release includes forward-looking statements regarding clinical development, noting that future results may differ from phase II findings.
Company
ALK Abello
Keywords
Copenhagen Stock Exchange:ALK B, ALK Abello, allergy